7332results about How to "Reduce release" patented technology

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

An object of the present invention is to provide an EL display device, which has a high operating performance and reliability. A third passivation film 45 is disposed under an EL element 203 which comprises a pixel electrode (anode) 46, and EL layer 47 and a cathode 48, to make a structure in which heat generated by the EL element 203 is radiated. Further, the third passivation film 45 prevents alkali metals within the EL element 203 from diffusing into the TFTs side, and prevents moisture and oxygen of the TFTs side from penetrating into the EL element 203. More preferably, heat radiating effect is given to a fourth passivation film 50 to make the EL element 203 to be enclosed by heat radiating layers.

A novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and / or a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble. A novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects. The novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe. Methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as welt a method for the preparation of a composition according to the invention.

A device for inducing weight loss in a patient includes a tubular prosthesis positionable at the gastro-esophageal junction region, preferably below the z-line. In a method for inducing weight loss, the prosthesis is placed such that an opening at its proximal end receives masticated food from the esophagus, and such that the masticated food passes through the pouch and into the stomach via an opening in its distal end.

The invention relates to an inorganic / organic nano-composite antibacterial and application of fiber product thereof. 0.01-20 proportions of inorganic antibacterial, 0.01-35 proportions of organic antibacterial, 0.0001-0.4 proportion of inorganic / organic antibacterial compatibility finishing agent, 0.05-40 proportions of macromolecule bond, 0.0001-0.4 proportion of stabilizer that prevents color change of the inorganic antibacterial, 0.1-30 proportions of high efficiency emulsifying agent and 100 proportions of distilled water are added in sequence by weight proportion, wetted, dispersed, ground, dispersed at high-speed, stirred, etc., so as to acquire the nano-composite antibacterial. The antibacterial can process the fiber product by a dip-dye method, a roll-dye method, a spray method, etc. Dresses, socks and socks, blankets, beddings, gowns, patient wears, masks, medicinal gauzes, air filtering nettings, etc., made from the inorganic / organic nano-composite antibacterial of the invention are characterized by high antibacterial efficiency, rapid antibacterial function, long lasting antibacterial performance, laundering durability, etc., and the inorganic / organic nano-composite antibacterial of the invention is applicable to life, medical care, etc., and has the functions of preventing the occurrence and transmission of diseases, protecting the health of people and improving life quality.

Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

The present invention relates to biscarbodiimides, thiourea derivatives, urea derivatives, and cross-linked hyaluronan derivatives having at least one intramolecular disulfide bond, and methods of preparation thereof. The invention also includes thiolated hyaluronan derivatives and salts thereof having at least one pendant thiol group or a modified pendant thiol group, and methods of preparation thereof. An example of a modified pendant thiol group is a sulfhydryl group linked to a small molecule such as a bioactive agent, for example a drug or pharmaceutically active moiety. A hyaluronan derivative having a sulfhydryl group linked to a pharmaceutically active moiety is useful as a sustained or controlled release drug delivery vehicle. Compositions containing the hyaluronan derivatives of the invention can reversibly viscosify in vivo or in vitro, in response to mild changes in condition, and are thus useful in ophthalmic surgery and in tissue engineering.

The present invention provides methods of using metal nanoparticles 0.5 to 400 nm in diameter to enhance the dose and effectiveness of x-rays or of other kinds of radiation in therapeutic regimes of ablating a target tissue such as tumor. The metal nanoparticles can be administered intravenously, intra-arterially, or locally to achieve specific loading in and around the target tissue. The metal nanoparticles can also be linked to chemical and / or biochemical moieties which bind specifically to the target tissue. The enhanced radiation methods can also be applied to ablate unwanted tissues or cells ex vivo.

The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

A stent capable of stably loading a biologically / physiologically active substance, without causing its decomposition or deterioration, and permitting it to release itself slowly over a long period of time without being rapidly released in a short period, after being implanted in a lesion. The stent (1) comprises a cylindrical stent main body (2) having an opening on each end and extending in axial direction between the two openings, and a sustained release coating formed on the surface of said stent main body from which a biologically / physiologically active substance is released, and wherein said sustained release coating is composed of a layer of a biologically / physiologically active substance (3) which covers the surface of said stent main body, and a polymer layer (4) which covers said layer of a biologically / physiologically active substance (3) on said layer of a biologically / physiologically active substance (3), and said layer of a biologically / physiologically active substance (3) contains at least one kind of fat-soluble biologically / physiologically active substance, and said polymer layer (4) contains a polymer miscible with said biologically / physiologically active substance and fine particles (5) equal to or smaller than 5 mum in particle diameter dispersed in the polymer.

Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.

A device for inducing weight loss in a patient includes a tubular prosthesis positionable at the gastro-esophageal junction region, preferably below the z-line. In a method for inducing weight loss, the prosthesis is placed such that an opening at its proximal end receives masticated food from the esophagus, and such that the masticated food passes through the pouch and into the stomach via an opening in its distal end.